MYBL2 and lung adenocarcinoma: Across two independent studies, elevated MYBL2 expression identified lung adenocarcinoma patients with significantly poorer OS and DFS outcomes, early onset disease, increased regional lymph node involvement, and increased prevalence of distant metastases (Figure 2, Table 1, Figure S3A).